SYDNEY, April 26 -- AsiaNet
JOHNSON ELECTRIC...
HONG KONG: Johnson Electric is scheduled to report its
annual results for the financial year ending 31st March 2004 on
7th June 2004. Ahead of its annual results announcement, the
company expects to hold discussions with securities analysts
and investors in the normal course of its business that may
cover aspects of Johnson Electric's performance for the year.
www.johnsonelectric.com
AVENTIS DEALBREAKER...
BASEL: Novartis announced today it decided to discontinue
negotiations and not submit a bid for a potential combination
of Aventis and Novartis' businesses. Novartis had entered
negotiations at the unanimous request of the Aventis
Supervisory Board as an alternative to Sanofi's hostile bid for
Aventis. Following Aventis' decision to engage in discussions
with Sanofi, at the strong intervention of the French
Government, Novartis decided not to proceed.
www.novartis.com
SYDNEY SOFTWARE...
FOLSOM, Calif: Meridian Project Systems, provider of
leading-edge enterprise software solutions for the real estate,
construction and facility lifecycle, announces the opening of
its new Asia Pacific office located in Sydney, Australia.
Meridian is commemorating this new office opening with two
launch events featuring its enterprise software solution,
Proliance.
www.mps.com
PUBLISHING FIRST...
In what appears to be a world first, Nielsen BookData
announced today that it will supply a Dynamic XML service from
its International database to global ebook aggregator, eBooks
Corporation. Publishers will be able to supplement their
metadata with information from the Nielsen BookData database
through Pi, eBooks' recently launched publisher interface. The
move will be a time-saver for publishers who often face a
daunting data-entry task in submitting their new titles to
ebook aggregators.
www.nielsenbookdata.com
GIGANTISM DRUG...
BASEL: Novartis announced today that the Japanese health
authority has approved Sandostatin LAR (octreotide acetate for
injectable suspension) for the treatment of acromegaly and
pituitary gigantism which is unresponsive to or unsuitable for
surgery or other drug therapies, and for symptoms associated
with gastrointestinal hormone secreting tumors (also known as
gastroenteropancreatic neuroendocrine tumors, including
carcinoid tumors, gastrinomas, and VIPomas (Vasoactive
Intestinal Peptide-secreting tumors).
www.novartisoncologyvpo.com
(AsiaNet is a consortium of leading news agencies
distributing unedited, translated news releases for worldwide
clients. Visit www.asianetnews.net for full-text versions.)